The core of the authors’ argument is that losing lean mass is not the same thing as losing functional muscle. When any person loses weight, whether through diet, surgery, or medication, the body sheds both fat and lean tissue because a lighter body simply demands less structural and metabolic support. A recent meta-analysis cited in the perspective found that lean mass accounted for roughly 25 to 39 percent of the total weight lost with incretin-based therapies, a proportion broadly comparable to the 26.2 percent observed with conventional lifestyle interventions. In other words, the fraction of weight loss coming from lean tissue during pharmacotherapy looks remarkably similar to what happens when patients lose weight the old-fashioned way, suggesting that the phenomenon reflects physiological body composition remodeling rather than a drug-specific pathology.

Real-world comparative data strengthen this interpretation considerably. In a cohort of 3,066 individuals, fat-free mass decreased by 11.7 percent after bariatric surgery but by only 3.3 percent during treatment with semaglutide or tirzepatide over 24 months. Meanwhile, fat mass fell far more dramatically, by 49.7 percent in the surgical group and 18.0 percent in the medication group. Crucially, in both groups the ratio of fat-free mass to fat mass improved, meaning patients ended up with a more favorable body composition than they started with. The authors contend that this pattern, in which adipose tissue declines disproportionately while most lean tissue is preserved, is difficult to reconcile with the notion of treatment-induced muscle wasting, although they acknowledge that a treatment-specific contribution cannot be entirely excluded.

Body composition sub-studies from the major clinical trial programs reinforce the point. In the STEP trials of semaglutide and the SURMOUNT program of tirzepatide, investigators documented marked reductions in total fat mass alongside preservation of most lean mass, yielding a net improvement in the lean-to-fat mass ratio despite modest absolute declines in lean tissue. Similar findings have emerged with oral semaglutide in people with type 2 diabetes, where fat mass declined significantly while skeletal muscle index and lean body mass remained largely unchanged. Taken together, these data suggest that incretin therapies preferentially strip away the tissue that is causing harm while leaving the metabolically active machinery of muscle largely intact.

Perhaps the most provocative element of the perspective is its argument that obesity itself damages muscle quality, so that weight loss may actually improve the muscle that remains. Excess adiposity promotes the accumulation of fat within muscle fibers, chronic low-grade systemic inflammation, mitochondrial dysfunction, and reduced contractile efficiency, producing muscle that is quantitatively larger but functionally inferior. Intentional weight loss appears to reverse several of these abnormalities: even as lean mass declines modestly, reductions in intramuscular lipid infiltration and inflammation, together with improvements in oxidative capacity, may enhance the functional quality of skeletal muscle. The authors invoke a memorable formulation to capture this idea: a smaller muscle is not necessarily a weaker muscle, and may in fact be metabolically healthier and more efficient than the enlarged, fat-infiltrated muscle it replaces.

The strongest evidence against the sarcopenia hypothesis comes from measurements of what muscles actually do. Across obesity trials, incretin therapy has consistently improved exercise capacity, physical performance, and mobility rather than degrading them. Multiple STEP studies demonstrated meaningful improvements in physical functioning and obesity-specific quality of life following semaglutide treatment, outcomes that are difficult to square with clinically relevant muscle loss, which would be expected to impair rather than enhance function. Evidence from bariatric surgery points in the same direction: despite substantial reductions in lean body mass during the first postoperative year, relative muscle strength, gait speed, chair-stand performance, and overall physical function consistently improve, changes long recognized as reflecting favorable physiological remodeling. Subgroup analyses of the major obesity trials have also shown comparable efficacy and safety of incretin therapies in participants aged 65 and older compared with younger adults, supporting their use in appropriately selected older patients.

None of this means the field can afford complacency, and the authors are careful to delineate who remains genuinely at risk. Sarcopenic obesity, the coexistence of excess adiposity with impaired muscle quantity, quality, and function, is a well-recognized clinical entity associated with frailty, disability, hospitalization, cardiometabolic complications, and increased mortality, and current consensus definitions emphasize function rather than mass alone. Older adults and individuals with pre-existing sarcopenia or frailty, low muscle strength, chronic inflammatory, kidney, or cardiovascular disease, prolonged physical inactivity, or inadequate nutritional intake are inherently more vulnerable to declines in muscle health regardless of which weight-loss strategy is employed. For these populations, the authors advocate a risk-stratified approach: baseline assessment and longitudinal monitoring of muscle strength and physical performance, attention to the rate of weight loss, and individualized nutritional support, whereas patients with preserved muscle reserve can generally be followed with routine clinical care.

The practical prescriptions that follow are grounded in established evidence rather than speculation. Adequate dietary protein intake, tailored to age, renal function, and nutritional status, should accompany pharmacological weight loss, and progressive resistance exercise should be regarded as an essential component of obesity treatment rather than an optional adjunct, complemented by aerobic activity to optimize cardiometabolic health. These recommendations align with current obesity guidelines and with studies showing that resistance training attenuates lean mass loss while improving muscle strength and physical performance during intentional weight loss. The authors also situate the muscle debate within the broader risk-benefit calculus of incretin therapy, noting that semaglutide has been shown to reduce major cardiovascular events in people with overweight or obesity and established cardiovascular disease, and that recent phase 3 data demonstrate benefits in metabolic dysfunction-associated steatohepatitis. Emerging analyses suggest these cardiovascular gains may not be fully explained by the magnitude of weight loss, pointing to anti-inflammatory and direct receptor-mediated effects that extend beyond adiposity reduction.

Significant knowledge gaps remain, and the perspective is candid about them. Long-term data extending beyond the duration of current clinical trials are limited, and the effects of incretin therapies in people with established sarcopenic obesity have barely been studied. The authors call for future research to prioritize muscle quality and function over lean mass alone, to establish standardized definitions of clinically meaningful muscle loss, and to test whether combining incretin drugs with resistance exercise, nutritional optimization, and emerging anabolic agents targeting the myostatin-activin signaling pathway can further optimize body composition and functional outcomes in high-risk groups. Skeletal muscle is also an endocrine organ, releasing myokines that regulate glucose and energy metabolism across organs, so substantial loss of functional muscle tissue could carry metabolic consequences beyond strength and mobility, a consideration that keeps the question scientifically live even as the clinical picture looks reassuring.

The conceptual shift the authors propose is ultimately about how medicine should judge success in obesity treatment. The field has already moved from counting kilograms to analyzing body composition, and the next step, they argue, is to focus on patient-centered outcomes: whether treatment leaves people healthier, stronger, and more functional. By that standard, the available evidence suggests that incretin therapies are restoring physiology rather than eroding it, preferentially removing the fat that drives disease while preserving, and possibly improving, the quality of the muscle that remains. Rather than viewing every kilogram of lean tissue lost as evidence of harm, clinicians should ask the harder and more meaningful question of whether patients can move better, live longer, and feel healthier, and on current evidence, the answer for most appears to be yes, provided that protein intake, resistance exercise, and vigilant monitoring of vulnerable patients remain part of the prescription.

Subject of Research: Body composition changes and sarcopenia risk during incretin-based obesity therapy

Article Title: Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern

Article References: Koufakis, T., Tentolouris, A., Karakasis, P., Popovic, D. S., & Patoulias, D. (2026). Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern. Advances in Therapy. https://doi.org/10.1007/s12325-026-03804-z

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03804-z

Keywords: incretin therapy, semaglutide, tirzepatide, obesity, sarcopenia, lean body mass, body composition, skeletal muscle, resistance exercise, muscle quality, bariatric surgery, cardiometabolic health